Hinge Health (HNGE) drew fresh attention after its recent close at US$88.59, prompting investors to reassess a business built around AI-assisted musculoskeletal care and steady revenue and net income expansion.
The pattern around Hinge Health over the past year is one of sharp share price momentum, with a 90 day share price return of 35.58% and a year to date share price gain of 94.45%, even though the 1 year total shareholder return is 53.72%.
See how Hinge Health fits into the broader AI-in-healthcare story by comparing it with 39 healthcare AI stocks.
After a run to US$88.59 and a wide gap between that quote, analyst targets near US$107.73 and a much lower intrinsic estimate, where does a reasonable fair value marker for Hinge Health actually sit?
Most Popular Narrative: 16.8% Undervalued
On the most followed view, Hinge Health’s fair value sits around $106.47, which is materially above the recent $88.59 close and frames a clear valuation gap.
Expansion of integrated digital and in person offerings through HingeSelect and broader provider network build out positions the company to pursue a larger share of MSK and adjacent care pathways, potentially increasing lives under contract and long term revenue per client.
Want to see what this expansion story assumptions really look like on a spreadsheet? The narrative refers to faster top line growth, rising margins and a richer earnings multiple. This raises the question of which of those levers contributes most to reaching that higher fair value.
Result: Fair Value of $106.47 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the Hinge Health story can unravel if employers pull back on digital MSK budgets or if AI tools trigger regulatory or data privacy setbacks.
Find out about the key risks to this Hinge Health narrative.
Another View On Hinge Health's Valuation
There is a very different signal once Hinge Health is priced on earnings. The stock trades on a P/E of 66.6x, compared with 24.8x for the wider US Healthcare sector and a 38.7x fair ratio estimate. That is a wide premium. Is the growth story strong enough to keep it there?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the Hinge Health story so far feels mixed, treat that as your prompt to review the numbers yourself and stress test every assumption. To understand why some investors still highlight potential upside, take a closer look at the 4 key rewards.
Looking for more investment ideas beyond Hinge Health?
Do not stop with a single stock. Use the Simply Wall Street Screener to quickly spot fresh ideas that match the kind of opportunities you care about.
- Target stronger value by reviewing the 31 high quality undervalued stocks that combine quality fundamentals with prices that sit below their estimated worth.
- Prioritise resilience by checking the list of solid balance sheet and fundamentals (23 results) so you can focus on companies with healthier financial footing.
- Hunt for early-stage potential through the 20 elite penny stocks with strong financials where you can scan for smaller players with stronger balance sheets than their share prices suggest.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com